GSK sees blockbuster potential in targeted cancer therapy after promising early data

0
187
British drugmaker GSK’s experimental targeted cancer drug Mo-rez has blockbuster potential, its head of oncology research has told reporters, after early data showed the drug helped ​shrink tumors in patients with advanced, hard-to-treat cancers.

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here